INDEX / DIRECTORY / TEVA PHARMACEUTICALS / MILITARY

Teva Pharmaceuticals MILITARY

MILITARY AUDIT UPDATED 2026-09-22
Military Score 1.00 /10 A Teva Pharmaceuticals - BDS-1000 811
Military 1.00

Evidence-only forensic audit. Scoring happens downstream - see the main dossier for the composite assessment.

Forensic audits like this are reader-funded - no sponsors, no ads. Support OpenIntel →

Direct Defence Contracting & Procurement

Teva Pharmaceutical Industries Limited is an Israeli-incorporated pharmaceutical group parent with principal executive offices in Tel Aviv-Jaffa.1 Teva was named among donors to the IDF Association for the Wellbeing of Israel’s Soldiers’ Adopt-a-Battalion programme in a 2014 report; the official IDF programme description states that participating companies commit donations for three years to combat units’ welfare budgets and welfare equipment.2, 3 This establishes a historical corporate welfare-donation channel, not a defence procurement contract or supply award.2, 3 KPMG’s December 2024 research reported that Teva was no longer listed as an active programme partner; the cessation date and any post-2020 participation remain unknown.4

During the October 2023 war, Teva stated that it worked through Le’Rufuah to donate medicines and medical equipment to “soldiers, victims, those evacuated from their homes or others in need.”5 Investigative reporting additionally described donations of medicines, baby-food compounds, and computers associated with the IDF response.6, 7 The available material characterises these as donations rather than procurement awards, and does not establish the precise recipients, quantities, delivery dates, or whether goods reached military rather than civilian medical channels.6, 7, 5

Teva has not been identified as Israel’s national pharmaceutical company in a formal defence-procurement framework, although Richard Francis publicly described Teva as “the national pharmaceutical company of Israel” following 7 October 2023.6 Teva Pharmaceuticals USA holds U.S. Department of Defense vaccine-contract activity, including delivery order SPE2DP25F4433 valued at $330,314 in March 2025; this concerns a U.S. DoD customer rather than an Israeli defence end-user.8

In May 2025, Israel’s Ministry of Defense announced requests for information concerning IDF medicines, medical equipment, and medical-equipment maintenance, but did not identify Teva as a respondent or awardee.9 The Ministry’s vendor portal lists medical equipment and medicines among sought vendor categories, without identifying Teva as a vendor.10 A January 2024 Israel Prison Service medicine-supply tender similarly does not identify Teva as an awardee.11

No public evidence identified of a verified Teva contract, tender award, framework agreement, memorandum of understanding, or named Medical Corps procurement instrument with IMOD, the IDF, Israel Border Police, or the Israel Prison Service beyond the historical welfare-programme and donation material described above.4, 9, 11, 10

Dual-Use Products & Tactical Variants

No public evidence identified that Teva manufactures or markets ruggedised, tactical, mil-spec, defence-grade, or end-user-specific military pharmaceutical variants.4, 1 Teva’s disclosed activities include generic, innovative, and biosimilar medicines; active pharmaceutical ingredients (APIs); contract manufacturing; distribution; and out-licensing, rather than purpose-built military products.1

Teva’s publicly described portfolio includes oral solids, injectables, inhalers, biosimilars, and APIs in ordinary pharmaceutical formats.4 Certain Teva generic medicines, including atropine sulfate injection, morphine, epinephrine, ciprofloxacin, and amoxicillin, may be standard medical supplies available to military medical services, but the reviewed material does not identify a Teva military specification, contract modification, or Israeli security end-user supply arrangement.4

The 2025 IMOD medicines RFI confirms that medicines can be sought for IDF use, but does not identify Teva products, bids, contracts, export licences, or end-user certificates.9 no public evidence identified of Teva-specific export-licence decisions, end-user certificates, or export-control reviews concerning Israeli military or security end-users.4, 1

Heavy Machinery, Construction & Infrastructure

Teva’s disclosed business concerns pharmaceutical manufacturing, R&D, APIs, distribution, and related services rather than heavy machinery, construction equipment, vehicles, or building materials.4, 1 no public evidence identified of Teva manufacturing heavy machinery, construction equipment, vehicles, or construction materials.4, 1

No public evidence identified of Teva construction, servicing, engineering, maintenance, or infrastructure contracts connected with settlements, checkpoints, the separation barrier, detention facilities, or military installations.4 KPMG recorded an uncorroborated report that a purported Teva subsidiary, MBT Biological Laboratories, moved from Atarot to Beit Shemesh around 2016; KPMG noted that the entity attribution and underlying evidence were not widely corroborated, so this is not treated as a verified Teva settlement facility or military-supply relationship.4

Supply Chain Integration with Defence Primes

No public evidence identified of Teva, Salomon, Levin & Elstein Ltd. (SLE), Medis, or Teva’s API business supplying components, APIs, specialist manufacturing, or services to Elbit Systems, Israel Aerospace Industries, Rafael Advanced Defense Systems, IMI/Elbit Land, or another Israeli defence prime.4, 1, 12

Teva’s manufacturing capabilities concern pharmaceutical APIs and finished-dose formulation rather than electronics, optics, structural metals, propellants, guidance systems, or weapons integration.4, 1 The 2025 proxy contains no text matches for Elbit, Rafael, or Israel Aerospace Industries; this is a limited document check rather than proof of the universal absence of relationships.12

No public evidence identified of Teva–defence-prime joint development, co-production, technology transfer, or licensed-manufacturing arrangements.4, 12 Teva continued to own and operate its API activities during 2025 while resuming a sales process for that business, but the filing does not identify a defence-prime relationship.1

Logistical Sustainment & Base Services

SLE remains a listed Israeli Teva subsidiary as of 31 December 2025.13 Teva’s 2025 Form 10-K states that distribution revenue in Israel derives through SLE, including distribution arrangements for third-party products; this supports current group attribution and Israeli civilian distribution activity, not military logistics.1, 13

Who Profits historically described SLE as Teva’s wholly owned distribution unit throughout Israel and the Occupied Palestinian Territory, and stated that it benefited from access to the Palestinian market under Paris Protocol economic arrangements.14, 15, 16 The Who Profits profile states that its information was valid through 22 July 2012, while current Teva disclosures do not identify OPT routes, warehouses, customers, settlement destinations, military end-users, or end-use controls.14, 15, 1, 13 Accordingly, the historical NGO material supports a broader, dated OPT-market allegation, not a verified current settlement-supply or military-logistics transaction.14, 15, 16

Teva’s 2024 filing confirms Israeli headquarters and several manufacturing and R&D facilities in Israel, and identifies regional military activity and employee reservist call-ups as operational risks.17 This establishes continuing Israeli operations, not a defence contract or supply relationship.17 The earlier site list including Kfar Saba, Netanya, Jerusalem, Petah Tikva, Ashdod, Ramat Hovav, and Shoham is historical; current reviewed filings do not reproduce that site-by-site list.4, 1

No public evidence identified of Teva or SLE contracts for catering, fuel, transport, facilities management, telecommunications, freight forwarding, port handling, waste management, or other base services for Israeli military or security installations.4, 1 no public evidence identified of a specific Teva/SLE settlement-supply route, military-base logistics route, or occupied-territory installation contract.14, 15, 1

Munitions, Weapons Systems & Strategic Platforms

Teva’s disclosed business is pharmaceutical rather than weapons-related.1 no public evidence identified that Teva or its operationally integrated businesses manufactures weapons, ammunition, explosive precursors for Israeli defence end-users, drones, military vehicles, naval platforms, missile-defence components, guidance systems, fire-control systems, kinetic-targeting AI, or other lethal or strategic military sub-systems.4, 1

No public evidence identified of Teva involvement in Iron Dome, David’s Sling, Arrow, fighter aircraft, tanks, warships, ballistic missile systems, or weapons-integration software.4, 1

Export Licensing, Regulatory & Legal History

Teva’s current Form 10-K describes general compliance exposure relating to trade controls and sanctions, but does not disclose an IDF or IMOD contract or a defence-export licence.1 no public evidence identified of any governmental grant, denial, suspension, or revocation of an export licence involving Teva products for Israeli military or security end-users.4, 1

No public evidence identified of a Teva-specific arms-embargo, sanctions, export-control enforcement action, judicial proceeding, or investigation concerning a defence supply relationship with Israel.4, 1 Teva Pharmaceuticals USA’s October 2023 Canadian federal-procurement suspension and its August 2023 U.S. DOJ deferred-prosecution resolution concerned civilian pharmaceutical price-fixing matters rather than defence trade.4

Civil Society Scrutiny & Documented Investigations

Who Profits categorised Teva under “Economic Exploitation” in relation to the Palestinian captive market and made historical claims concerning SLE’s logistics and pharmaceutical-market access; the relevant profile limits its information to July 2012.14, 15, 16 The American Friends Service Committee similarly characterises Teva as part of an oligopoly benefiting from sales to a Palestinian captive market; this is civil-society analysis rather than direct proof of military supply.18

Teva was not included in the final 2020 OHCHR settlement-business database publication, and it remained unlisted in the September 2025 update.19, 20 Teva was also not named in A/HRC/59/23, including its military, surveillance/carcerality, and heavy-machinery discussion.21 These are document-scoped absences and do not establish the absence of all settlement or military nexus beyond the respective publications’ scope.19, 20, 21

The reviewed material reports exclusion of Teva by Danish pension funds, including AkademikerPension, over Israel-linked concerns; the underlying pension-fund decisions were not retrieved, so the stated rationale remains secondary-source reporting.22 A BankTrack/DBIO reference identifying an April 2025 ABP divestment is a lead only, because no underlying ABP decision or Teva-specific rationale was obtained.4 BDS Italia has published a Teva-focused campaign dossier, establishing an organised boycott campaign; its allegations of continuing post-2023 military logistical support were not independently verified and are not treated as findings.23

Teva’s 2025 sustainability materials describe supplier-sustainability evaluation and high-risk third-party due diligence, but do not identify a policy specifically governing military customers, occupied-territory end use, prisoner healthcare, or Israeli security-force supply.24, 25

Teva’s current corporate disclosures identify Richard Francis as President, CEO, and director, and Dr. Sol J. Barer as Board Chair; the board includes Rosemary Crane, Amir Elstein, Chen Lichtenstein, Gerald Lieberman, Roberto Mignone, Perry Nisen, Ronit Satchi-Fainaro, and Tal Zaks.26, 27 Amir Elstein remains a Teva director and is identified by Teva as Chairman of Tower Semiconductor and Chairman of the Israel Democracy Institute.28, 26, 12 The reviewed current materials do not identify these named directors or executives as Friends of the IDF directors, and FIDF’s own leadership list does not name them.26, 27, 29, 30 This finding is limited to the reviewed disclosures and does not constitute a complete person-by-person affiliation review.12, 31, 29

Teva’s 2024 and 2025 filings establish continuing Israeli operations through 2025 and identify regional military activity and employee reservists as operational risks, but do not establish continuation after July or November 2024 of the historical Adopt-a-Battalion participation, 2023 soldier-directed donations, or any direct Israeli-military supply relationship.1, 17

Footnotes

  1. https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612d10k.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21

  2. https://www.idf.il/98093/ ↩ ↩2

  3. https://www.israelnationalnews.com/news/181476 ↩ ↩2

  4. https://www.sykehusinnkjop.no/4b01f0/siteassets/bilder/nyheter/2024/gransking-teva/kpmg-targeted-research-teva-december-2024.pdf ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21

  5. https://www.tevapharm.com/globalassets/tevapharm-vision-files/teva-esg-progress-report-2023.pdf ↩ ↩2

  6. https://stopteva.nl/wp-content/uploads/2025/07/20250615_Teva_and_the_IDF_Repill-.pdf ↩ ↩2 ↩3

  7. https://www.declassifieduk.org/the-israeli-firm-aiding-the-nhs-and-idf ↩ ↩2

  8. https://www.govchime.com/market-intelligence/awards/CONT_AWD_SPE2DP25F4433_9700_SPE2DP20D0002_9700 ↩

  9. https://www.online.mod.gov.il/Online2016/pages/general/News/SingleMessage.aspx?id=464&tType=1 ↩ ↩2 ↩3

  10. https://mission-ny.mod.gov.il/technical ↩ ↩2

  11. https://mr.gov.il/ilgstorefront/he/p/4000581061 ↩ ↩2

  12. https://www.sec.gov/Archives/edgar/data/818686/000119312525076829/d901192ddef14a.htm ↩ ↩2 ↩3 ↩4 ↩5

  13. https://www.sec.gov/Archives/edgar/data/818686/000119312526034532/d93612dex21.htm ↩ ↩2 ↩3

  14. https://www.whoprofits.org/companies/company/4212 ↩ ↩2 ↩3 ↩4 ↩5

  15. https://www.whoprofits.org/companies/company/4243 ↩ ↩2 ↩3 ↩4 ↩5

  16. https://www.whoprofits.org/writable/uploads/publications/1668626890_1aa4455a6a4cc3b32b5d.pdf ↩ ↩2 ↩3

  17. https://www.sec.gov/Archives/edgar/data/818686/000119312525020826/d865574d10k.htm ↩ ↩2 ↩3

  18. https://investigate.afsc.org/company/teva-pharmaceutical-industries ↩

  19. https://www.ohchr.org/en/press-releases/2025/09/un-human-rights-office-updates-database-businesses-involved-israeli ↩ ↩2

  20. https://www.ohchr.org/en/pages/business-involved-israeli-settlements ↩ ↩2

  21. https://www.ohchr.org/en/documents/hr-bodies/hrc/sp-sessions/A-HRC-59-23-en ↩ ↩2

  22. https://amwatch.com/AMNews/Pension/article18600232.ece ↩

  23. https://bdsitalia.org/index.php/teva-campagna/3000-teva-campagna ↩

  24. https://www.tevapharm.com/our-company/sustainability-impact/previous-reports/healthy-future-report/esg-report-2024-healthy-future-we-want-to-see/ ↩

  25. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2025/Tevas-2024-Healthy-Future-Report-Highlights-Sustainability-Progress-Including-Surpassed-Targets-Linked-to-Financial-Strategy/default.aspx ↩

  26. https://www.tevapharm.com/our-company/leadership-governance/board-of-directors ↩ ↩2 ↩3

  27. https://www.tevapharm.com/our-company/leadership-governance/corporate-executives ↩ ↩2

  28. https://www.tevapharm.com/our-company/leadership-governance/board-of-directors/amir-elstein ↩

  29. https://www.fidf.org/leadership/ ↩ ↩2

  30. https://www.fidf.org/financials/ ↩

  31. https://www.sec.gov/Archives/edgar/data/818686/000119312526134756/d11977ddef14a.htm ↩